Perihilar cholangiocarcinoma (PHCC) can be cured only by excision of the extrahepatic bile duct with partial liver resection, a procedure associated with mortality rates exceeding 10 per cent 1 . This susceptibility to postoperative death results in part from tumour-induced cholestasis, which is a major risk factor in liver surgery 2, 3 . Patients with PHCC therefore routinely undergo preoperative biliary drainage (PBD), during which bile flow into the intestines is restored. PBD reportedly improves outcomes after liver resection for PHCC 4, 5 . PBD is used routinely, but this is based on limited preclinical evidence and an incomplete understanding of the pathophysiology and resolution of cholestasis. A rationale for performing PBD beyond normalizing bilirubin levels is currently lacking. Consequently, there is no consensus on the optimal timing, extent or technique of PBD for patients with PHCC 6, 7 .
The aims of this study were to explore how cholestasis hampers hepatic resilience to surgery and to investigate whether PBD reverses these effects. To do so, paired biopsies of cholestatic and drained (after PBD) liver tissue were obtained from eight patients with suspected PHCC. All patients with PHCC underwent unilateral PBD, meaning that only the outflow of bile from the future remnant liver (FRL) was restored (Fig. 1) . The control group consisted of liver tissue from eight patients undergoing major liver resection for any malignancy other than PHCC or for a benign liver lesion. Patients with parenchymal liver disease were excluded from the control group. Gene expression profiles in cholestatic liver tissue, drained liver tissue (after PBD) and healthy liver tissue were subsequently studied by microarray analysis. Details of the methods can be found in Appendix S1 (supporting information).
The clinical characteristics are summarized in Table S1 (supporting information). The greatest differences in gene expression were observed in cholestatic versus control tissue (1032 genes), followed by drained versus cholestatic tissue (338 genes) and drained versus control tissue (318 genes) (Fig. S1, supporting information) . This suggests that PBD largely corrected the cholestatic gene expression profile towards a native state. No genes were either upregulated or downregulated in all three comparisons. The ten most upregulated and downregulated genes in each comparison are detailed in Fig. S2 , Tables S2-S4 and  Tables S9 -S11 (supporting information) .
Several genes involved in extracellular matrix deposition and transforming growth factor (TGF) β signalling (such as LOXL4 and MMP7) were upregulated in cholestasis versus control tissue, indicating cholestasis-induced activation of profibrotic signalling. In addition, two of the ten most upregulated genes, UBD and CD24, are hepatic carcinogens 8, 9 . Notable downregulated genes were involved in cellular proliferation (IGF1 and IGFALS). Genes upregulated in the drained versus cholestasis group were mostly involved in anabolic pathways such as cholesterol metabolism (LCAT) and amino acid metabolism (ASPG), suggesting a (partial) restoration of hepatocyte function following PBD. Downregulated genes in this group appeared non-specific.
Gene set enrichment analysis (Tables S5 -7 , supporting information) revealed 14 affected gene sets in the cholestasis versus control group, five of which were increased. These included gene sets associated with hepatic tumorigenicity and inflammation (Table S5 , supporting information). A reduction in expression was seen in gene sets reflecting anabolic processes, normal liver function and hepatocyte differentiation. In the drained versus cholestasis samples, two gene sets were increased and nine were downregulated (Table S6 , supporting information). In contrast to the cholestasis versus control group, the gene set reflecting hepatocyte function (SU_LIVER) was upregulated, again indicative of functional hepatic recovery following PBD. Inflammatory gene sets were downregulated in the drainage versus cholestasis group, including those involved in tumour necrosis factor (TNF) α and inflammasome signalling.
Subsequently, a pathway analysis was performed focusing on TNF-α, inflammasome and TGF-β signalling for the cholestasis versus control and drained versus cholestasis groups ( Fig. 2; Table S8 , supporting information). In accordance with the aforementioned results, cholestasis triggered upregulation of inflammatory TNF-α signalling cascades in the cholestasis versus control group (Fig. 2a) . Expression of these genes was decreased in the drained versus cholestasis group, indicating diminished TNF-α signalling after PBD. A similar trend was noted for the expression of genes involved in inflammasome formation (Fig. 2b) , indicating that PBD reduced cholestasis-induced hepatic inflammation.
As inflammation is a strong profibrotic trigger, the upregulation of TGF-β target genes in the cholestasis versus control group corresponded well with the data on TNF-α and inflammasome signalling (Fig. 2c) 10 . The most important genes affected in the cholestasis versus control group included those encoding extracellular matrix component collagen (such as COL1A1/2) and tissue inhibitors of matrix metalloproteinases (for example TIMP1) (Fig. 1c) . Alleviation of cholestasis (drained versus cholestasis group) resulted in decreased expression of TGF-β target genes.
These data show that, in patients with suspected PHCC undergoing unilateral PBD, inflammatory and fibrotic signalling cascades are activated in the cholestatic liver segments at the time of surgery. The activation of these pathways was largely (but not fully) reversed following unilateral PBD, which may have several implications. It shows that the commonly long interval between presentation and surgery in patients with PHCC triggers alterations in gene expression typically seen in advanced cholestatic liver disease 10 . Such ramifications are also evident at a histological level, as the onset of bridging fibrosis was seen in the (cholestatic) resection specimens from patients with PHCC who had undergone unilateral PBD 11 . The severity of these changes supports the use of PBD of the FRL. Another implication relates to complications seen during the preoperative evaluation. PBD can cause cholangitis and pancreatitis (Table S1 , supporting information), which are potentially lethal complications that need to resolve before surgery. Recent series suggest that these drawbacks of PBD may outweigh the benefits in patients with a FRL volume exceeding approximately 50 per cent 1 .
When PBD is indicated (in patients with a small FRL or cholangitis at presentation), the interval between successful drainage and surgery should probably be substantial. Although plasma bilirubin levels normalize rapidly after PBD, the effects on liver gene expression profiles were largely, but not fully, reversed in PBD-treated liver segments at the time of surgery. It is therefore conceivable that the restoration of functional liver tissue in a PBD-treated FRL takes considerably longer than the normalization of serum markers. When PBD is not indicated (for example when the FRL volume exceeds 50 per cent), there may be room for pharmacological alternatives. Based on the present results (Fig. S2, supporting information) and recent literature, inhibiting profibrotic lysyl oxidase-like (LOXL) proteins may decelerate cholestasis-induced fibrogenesis 12 . Agents targeting TNF-α or inflammasome signalling have already been approved for other indications. Candidates that specifically target cholestatic liver injury, such as fibroblast growth factor (FGF) 19 analogues, have also been introduced 10, 13 . Such strategies may even decrease the FRL volume above which PBD should be avoided 1 . In . Grey gene boxes indicate probes that were of poor quality or probes that were not included in the gene expression analysis. Some genes are represented by two or more boxes because multiple probes for this gene were included in the microarray. A functional description of all depicted genes is included in Table S8 (supporting  information) . ROS, reactive oxygen species these patients, liver resection should ideally be performed early after presentation, analogous to the situation for certain patients with pancreatic cancer 14 . Increasing the number of patients with PHCC undergoing surgery without PBD could reduce preoperative complications. Such improvements are urgently needed to reduce the substantial risks currently associated with liver resection for PHCC.
